



Date: 7 March 2017

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

RESTRICTED SECURITIES RELEASED FROM ESCROW

Noxopharm Limited (ASX: NOX) advises that in accordance with ASX Listing Rule 3.10A, the following restricted securities are being released from escrow:

| Security Description | Number | Date of Release |
|----------------------|-----------|-----------------|
| Ordinary Shares | 4,261,214 | 1 April 2017 |

It is noted that although the Ordinary Shares are being released from escrow, they are not currently quoted on the ASX and as such quotation of these ordinary shares will be sought in accordance with ASX Listing Rule 2.8.2.

It is further noted that the following unlisted restricted securities are also being released from escrow:

| Security Description | Number | Date of Release |
|---|-----------|-----------------|
| Unlisted Options (\$0.30, Expiry 28 February 2021) | 3,277,858 | 1 April 2017 |

Both of the abovementioned security classes relate to seed capital raisings prior to the listing and capital raising of NOX under the prospectus dated 24 June 2016.

The majority of the total seed capital ordinary shares and options remain under escrow as outlined below:

- 36,885,465 ordinary shares, escrowed until 24 months from listing (being 9 August 2018);
- 10,000,000 performance shares, escrowed until 24 months from listing (being 9 August 2018); and
- 18,950,358 unlisted options (30 cents expiring 28 February 2021), escrowed until 24 months from listing (being 9 August 2018).

Yours sincerely,
David Franks
Company Secretary

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. The purpose is to ensure that most idronoxil administered remains in an active form rather than as inactive Phase 2 metabolites.

Idronoxil works by cancelling mechanisms (such as PARP1/Akt) in cancer cells that allow those cells to resist the killing effects of chemotherapies and radiotherapy. Idronoxil targets an external NADH oxidase, ENOX 2, responsible for maintaining the transmembrane electron potential (TMEP) in the plasma membrane. Inhibition of this enzyme causes loss of TMEP and disruption of key downstream pro-survival mechanisms including PARP1/Akt/PI3 kinase. ENOX2 is an oncogene whose expression is restricted to cancer cells.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Melbourne. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

INVESTOR AND MEDIA ENQUIRIES: Prue Kelly
E: info@noxopharm.com T: + 61 2 9144 2223

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.